Welcome to our dedicated page for Kewaunee Scienti news (Ticker: KEQU), a resource for investors and traders seeking the latest updates and insights on Kewaunee Scienti stock.
Kewaunee Scientific Corporation reports developments tied to its laboratory, healthcare and technical furniture business. The company designs, manufactures and installs steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks for laboratory and research environments.
Recurring KEQU news includes quarterly operating results, Domestic and International segment performance, Nu Aire integration and product expansion, debt refinancing, commercial leadership appointments, and global sales activity. Updates also cover the company's laboratory infrastructure and biosafety product portfolio, including Nu Aire biological safety cabinets, CO2 incubators, ultralow freezers, and related laboratory equipment.
Kewaunee Scientific (NASDAQ: KEQU) appointed Jorge Santos as Vice President, International Sales, Laboratory Products Group, effective April 14, 2026. Santos, based in Madrid, brings over 20 years of international commercial leadership across 25+ countries to support global expansion following the NuAire acquisition. The move targets deeper penetration in Europe, Middle East, Asia, and continued strength in India under existing leadership.
The company said Santos will report to CEO Thomas D. Hull III and work alongside regional leaders to leverage Kewaunee and NuAire portfolios for integrated laboratory solutions worldwide.
Kewaunee Scientific (NASDAQ: KEQU) reported fiscal 2026 third quarter results for the period ended January 31, 2026. Net sales were $69,399,000, up 3.3% year-over-year. Pre-tax earnings were $1,604,000 (+25.8%), while net earnings declined to $692,000 from $1,354,000. Diluted EPS was $0.23 versus $0.45 a year earlier.
The Company's order backlog was $183.2 million, cash on hand $10.347 million, and debt-to-equity was 0.68-to-1. Management noted integration of the acquired Nu Aire and continued corporate investments supporting growth and SEC reporting readiness.
Kewaunee Scientific (NASDAQ: KEQU) and its recently acquired subsidiary Nu Aire will attend analytica 2026 in Munich, March 24–27, exhibiting integrated laboratory infrastructure and biosafety solutions with channel partner ibs tecnomara at Booth B1.110.
The companies will showcase casework, fume hoods, Class II biosafety cabinets, controlled environment systems, and regional support for European lab projects.
Kewaunee Scientific (NASDAQ: KEQU) said it will release third quarter fiscal 2026 results on Wednesday, March 11, 2026 after market close. Results will be posted on the company website.
The announcement reiterates corporate profile, global manufacturing footprint and the recently acquired subsidiary Nu Aire.
Unusual Machines (NYSE American: UMAC) received a $2.1 million purchase order for NDAA-compliant drone components to support domestically assembled drone systems for defense and government applications.
The order will be fulfilled across Q1 and Q2 2026, using existing manufacturing capacity and inventory. Components include Rotor Riot Brave flight controllers and ESCs, Fat Shark Aura analog cameras and VTX, HDO+ headsets, and motors. Management said operational alignment enables rapid execution to meet compressed government timelines.
Kewaunee Scientific (NASDAQ: KEQU) reported fiscal 2026 second quarter results for the period ended October 31, 2025. Net sales were $70.096 million, up 46.8% year-over-year. EBITDA was $5.79 million, higher than the prior-year quarter. Pre-tax earnings were $3.453 million (down 12.2%) and net earnings were $2.445 million. Diluted EPS was $0.82.
The company reported an b$order backlog of $192.9 million$55.224 million (+51.7%), and international sales of $14.872 million (+31.0%). Cash on hand was $13.679 million. Management cited project delivery timing volatility and noted the contribution from the recently acquired Nu Aire to results.
Kewaunee Scientific (NASDAQ: KEQU) announced on Dec 4, 2025 that it fully repaid its Seller Notes tied to the Nu Aire acquisition. The Seller Notes had an original principal of $23.0 million and were scheduled to mature Nov 1, 2027. Repayment was funded via an amendment to the Nov 1, 2024 loan agreement with PNC, which provided a $10.0 million term loan and permitted use of available revolving credit.
The company said the transactions lower overall debt, reduce the effective interest rate, and materially cut expected future interest expense while supporting strategic growth plans.
Kewaunee Scientific (NASDAQ: KEQU) announced it will release its second quarter fiscal year 2026 financial results on Wednesday, December 10, 2025 after the close of trading. The company said the release will be posted on its website and accompanying materials will be available at www.kewaunee.com.
The release reiterates company background: Kewaunee designs and manufactures laboratory and healthcare furniture, operates manufacturing sites in Statesville and Bangalore, and recently acquired subsidiary Nu Aire, a maker of biological safety cabinets and lab equipment. The notice includes customary forward-looking statements and risk factors and provides an investor contact.
Kewaunee Scientific Corporation (NASDAQ: KEQU), a leading manufacturer of laboratory, healthcare, and technical furniture products, has appointed J. Jette Campbell, CPA to its Board of Directors, effective September 10, 2025. Campbell brings extensive experience from leadership roles at PepsiCo, Frito-Lay, and Griffin LLC, as well as expertise as a partner at Carl Marks Advisors.
The appointment comes at a strategic time as Kewaunee focuses on accelerating growth through organic and inorganic means. The company, founded in 1906, operates manufacturing facilities in Statesville, North Carolina and Bangalore, India, with its recently acquired subsidiary Nu Aire based in Minnesota, complementing Kewaunee's product portfolio with biological safety cabinets and laboratory equipment.
Kewaunee Scientific (NASDAQ: KEQU) reported strong Q1 FY2026 results with sales reaching $71.1 million, up 46.9% year-over-year. The company achieved net earnings of $3.1 million ($1.04 per diluted share), compared to $2.2 million ($0.74 per share) in the prior year.
The company's order backlog stood at $205.0 million as of July 31, 2025, up from $159.4 million year-over-year. Domestic segment sales increased 53.0% to $54.4 million, while International segment sales grew 30.2% to $16.8 million. The growth was partially driven by the incorporation of Nu Aire's results, following its acquisition in November 2024.
Despite anticipating uneven quarterly performance for the remainder of FY2026, management expects to deliver improved unadjusted EBITDA compared to FY2025, while continuing strategic investments in corporate infrastructure.
[ "Sales increased significantly by 46.9% to $71.1 million year-over-year", "Net earnings grew 41% to $3.1 million compared to prior year", "Strong order backlog of $205.0 million, up 28.6% from prior year", "Domestic segment sales surged 53.0% to $54.4 million", "International segment sales increased 30.2% to $16.8 million", "Debt-to-equity ratio improved to 0.94-to-1 from 0.99-to-1" ]